T1 mapping in cardiomyopathy at cardiac MR: Comparison with endomyocardial biopsy

Radiology

Volumn 265, Issue 3, 2012, Pages 724-732

  Sibley, Christopher T ^a   Noureldin, Radwa A ^a   Gai, Neville ^a   Nacif, Marcelo Souto ^a,b   Liu, Songtao ^a   Turkbey, Evrim B ^a   Mudd, James O ^c   Van Der Geest, Rob J ^d   Lima, João A C ^b   Halushka, Marc K ^b   Bluemke, David A ^a  

^a NATIONAL INSTITUTES OF HEALTH   (United States)

^b JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c OREGON HEALTH AND SCIENCE UNIVERSITY   (United States)

^d LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

GADODIAMIDE; GADOLINIUM PENTETATE MEGLUMINE;

ADOLESCENT; ADULT; AGED; AREA UNDER THE CURVE; ARTICLE; CARDIOMYOPATHY; CARDIOVASCULAR MAGNETIC RESONANCE; CLINICAL ARTICLE; CONTRAST ENHANCEMENT; CONTROLLED STUDY; DIAGNOSTIC TEST ACCURACY STUDY; DIGITAL IMAGING; FEMALE; GRADIENT ECHO INVERSION RECOVERY SEQUENCE; HEART FAILURE; HEART MUSCLE BIOPSY; HEART MUSCLE FIBROSIS; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; IMAGE ANALYSIS; IMAGE QUALITY; IMAGING SOFTWARE; INVERSION RECOVERY LOOK LOCKER SEQUENCE; MALE; NUCLEAR MAGNETIC RESONANCE IMAGING; NUCLEAR MAGNETIC RESONANCE SCANNER; PRIORITY JOURNAL; QUANTITATIVE ANALYSIS; REFERENCE VALUE; RETROSPECTIVE STUDY; STAINING;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; ALGORITHMS; BIOPSY; CARDIOMYOPATHIES; CHI-SQUARE DISTRIBUTION; CONTRAST MEDIA; ENDOMYOCARDIAL FIBROSIS; FEMALE; GADOLINIUM DTPA; HUMANS; IMAGE INTERPRETATION, COMPUTER-ASSISTED; MAGNETIC RESONANCE IMAGING; MALE; MIDDLE AGED; RETROSPECTIVE STUDIES; STAINING AND LABELING; STATISTICS, NONPARAMETRIC;

EID: 84870009574     PISSN: 00338419     EISSN: 15271315     Source Type: Journal    
DOI: 10.1148/radiol.12112721     Document Type: Article

References (35)

1. Kwon DH, Halley CM, Carrigan TP, et al. Extent of left ventricular scar predicts outcomes in ischemic cardiomyopathy patients with significantly reduced systolic function: a delayed hyperenhancement cardiac magnetic resonance study. JACC Cardiovasc Imaging 2009;2(1):34-44.
2. Bruder O, Wagner A, Jensen CJ, et al. Myocardial scar visualized by cardiovascular magnetic resonance imaging predicts major adverse events in patients with hypertrophic cardiomyopathy. J Am Coll Cardiol 2010; 56(11):875-887.
3. Kwong RY, Chan AK, Brown KA, et al. Impact of unrecognized myocardial scar detected by cardiac magnetic resonance imaging on event-free survival in patients presenting with signs or symptoms of coronary artery disease. Circulation 2006;113(23):2733-2743. (Pubitemid 43947991)
4. Kim RJ, Wu E, Rafael A, et al. The use of contrast-enhanced magnetic resonance imaging to identify reversible myocardial dysfunction. N Engl J Med 2000;343(20):1445-1453.
5. Nazarian S, Bluemke DA, Lardo AC, et al. Magnetic resonance assessment of the substrate for inducible ventricular tachycardia in nonischemic cardiomyopathy. Circulation 2005;112(18):2821-2825. (Pubitemid 41641676)
6. Simonetti OP, Kim RJ, Fieno DS, et al. An improved MR imaging technique for the visualization of myocardial infarction. Radiology 2001;218(1):215-223. (Pubitemid 32151298)
7. Wu E, Judd RM, Vargas JD, Klocke FJ, Bonow RO, Kim RJ. Visualisation of presence, location, and transmural extent of healed Q-wave and non-Q-wave myocardial infarction. Lancet 2001;357(9249):21-28. (Pubitemid 32056497)
8. Thomson LE, Kim RJ, Judd RM. Magnetic resonance imaging for the assessment of myocardial viability. J Magn Reson Imaging 2004; 19(6):771-788. (Pubitemid 38788659)
9. Rehwald WG, Fieno DS, Chen EL, Kim RJ, Judd RM. Myocardial magnetic resonance imaging contrast agent concentrations after reversible and irreversible ischemic injury. Circulation 2002;105(2):224-229. (Pubitemid 34084323)
10. Wagner A, Mahrholdt H, Thomson L, et al. Effects of time, dose, and inversion time for acute myocardial infarct size measurements based on magnetic resonance imaging-delayed contrast enhancement. J Am Coll Cardiol 2006;47(10):2027-2033.
11. Flett AS, Hayward MP, Ashworth MT, et al. Equilibrium contrast cardiovascular magnetic resonance for the measurement of diffuse myocardial fibrosis: preliminary validation in humans. Circulation 2010;122(2): 138-144.
12. Nigri M, Azevedo CF, Rochitte CE, et al. Contrast-enhanced magnetic resonance imaging identifies focal regions of intra-myocardial fibrosis in patients with severe aortic valve disease: Correlation with quantitative histopathology. Am Heart J 2009; 157(2):361-368.
13. Iles L, Pfluger H, Phrommintikul A, et al. Evaluation of diffuse myocardial fibrosis in heart failure with cardiac magnetic resonance contrast-enhanced T1 mapping. J Am Coll Cardiol 2008;52(19):1574-1580.
14. Selvin E, Najjar SS, Cornish TC, Halushka MK. A comprehensive histopathological evaluation of vascular medial fibrosis: insights into the pathophysiology of arterial stiffening. Atherosclerosis 2010;208(1):69-74.
15. Karlsson M, Nordell B. Analysis of the Look-Locker T(1) mapping sequence in dynamic contrast uptake studies: simulation and in vivo validation. Magn Reson Imaging 2000;18(8):947-954.
16. Amano Y, Takayama M, Kumita S. Contrastenhanced myocardial T1-weighted scout (Look-Locker) imaging for the detection of myocardial damages in hypertrophic cardiomyopathy. J Magn Reson Imaging 2009; 30(4):778-784.
17. Gai N, Turkbey EB, Nazarian S, et al. T1 mapping of the gadolinium-enhanced myocardium: adjustment for factors affecting interpatient comparison. Magn Reson Med 2011; 65(5):1407-1415.
18. Nacif MS, Turkbey EB, Gai N, et al. Myocardial T1 mapping with MRI: comparison of look-locker and MOLLI sequences. J Magn Reson Imaging 2011;34(6):1367-1373.
19. Mahrholdt H, Wagner A, Judd RM, Sechtem U, Kim RJ. Delayed enhancement cardiovascular magnetic resonance assessment of non-ischaemic cardiomyopathies. Eur Heart J 2005;26(15):1461-1474. (Pubitemid 41373486)
20. Assomull RG, Prasad SK, Lyne J, et al. Cardiovascular magnetic resonance, fibrosis, and prognosis in dilated cardiomyopathy. J Am Coll Cardiol 2006;48(10):1977-1985. (Pubitemid 44738448)
21. Kwong RY, Sattar H, Wu H, et al. Incidence and prognostic implication of unrecognized myocardial scar characterized by cardiac magnetic resonance in diabetic patients without clinical evidence of myocardial infarction. Circulation 2008;118(10):1011-1020.
22. Breuckmann F, Möhlenkamp S, Nassenstein K, et al. Myocardial late gadolinium enhancement: prevalence, pattern, and prognostic relevance in marathon runners. Radiology 2009;251(1):50-57.
23. Appelbaum E, Maron BJ, Adabag S, et al. Intermediate-signal-intensity late gadolinium enhancement predicts ventricular tachyarrhythmias in patients with hypertrophic cardiomyopathy. Circ Cardiovasc Imaging 2012;5(1):78-85.
24. Cooper LT, Baughman KL, Feldman AM, et al. The role of endomyocardial biopsy in the management of cardiovascular disease: a scientific statement from the American Heart Association, the American College of Cardiology, and the European Society of Cardiology. Circulation 2007;116(19):2216-2233. (Pubitemid 350060359)
25. Zannad F, Alla F, Dousset B, Perez A, Pitt B. Limitation of excessive extracellular matrix turnover may contribute to survival benefit of spironolactone therapy in patients with congestive heart failure: insights from the randomized aldactone evaluation study (RALES). Rales Investigators. Circulation 2000;102(22):2700-2706.
26. Brooks A, Schinde V, Bateman AC, Gallagher PJ. Interstitial fibrosis in the dilated non-ischaemic myocardium. Heart 2003;89(10):1255-1256. (Pubitemid 37164032)
27. Schalla S, Bekkers SC, Dennert R, et al. Replacement and reactive myocardial fibrosis in idiopathic dilated cardiomyopathy: comparison of magnetic resonance imaging with right ventricular biopsy. Eur J Heart Fail 2010; 12(3):227-231.
28. Beltrami CA, Finato N, Rocco M, et al. Structural basis of end-stage failure in ischemic cardiomyopathy in humans. Circulation 1994;89(1):151-163. (Pubitemid 24026485)
29. Marijianowski MM, Teeling P, Becker AE. Remodeling after myocardial infarction in humans is not associated with interstitial fibrosis of noninfarcted myocardium. J Am Coll Cardiol 1997;30(1):76-82. (Pubitemid 27357128)
30. Volders PGA, Willems IEMG, Cleutjens JPM, Arends JW, Havenith MG, Daemen MJAP. Interstitial collagen is increased in the non-infarcted human myocardium after myocardial infarction. J Mol Cell Cardiol 1993; 25(11):1317-1323. (Pubitemid 24003838)
31. Ardehali H, Qasim A, Cappola T, et al. Endomyocardial biopsy plays a role in diagnosing patients with unexplained cardiomyopathy. Am Heart J 2004;147(5):919-923. (Pubitemid 38881009)
32. Lamke GT, Allen RD, Edwards WD, Tazelaar HD, Danielson GK. Surgical pathology of subaortic septal myectomy associated with hypertrophic cardiomyopathy. A study of 204 cases (1996-2000). Cardiovasc Pathol 2003; 12(3):149-158. (Pubitemid 36581893)
33. Messroghli DR, Greiser A, Fröhlich M, Dietz R, Schulz-Menger J. Optimization and validation of a fully-integrated pulse sequence for modified look-locker inversion-recovery (MOLLI) T1 mapping of the heart. J Magn Reson Imaging 2007; 26(4):1081-1086. (Pubitemid 47548170)
34. Lee JJ, Liu S, Nacif MS, et al. Myocardial T1 and extracellular volume fraction mapping at 3 tesla. J Cardiovasc Magn Reson 2011;13(1):75.
35. Kass DA, Bronzwaer JGF, Paulus WJ. What mechanisms underlie diastolic dysfunction in heart failure? Circ Res 2004;94(12):1533-1542. (Pubitemid 38856960)